This reimbursement approval is a positive catalyst for BrainsWay's financial outlook. It potentially opens up a new revenue stream in the Israeli market, particularly given the increased focus on PTSD treatment following recent events. However, the financial impact may be gradual as the reimbursement is initially to public hospitals. Investors should consider the scalability of this opportunity. If BrainsWay succeeds in expanding reimbursement to private clinics and more medical centers, it could significantly boost the company's revenue. The addressable market size and the potential for international replication of this reimbursement model in other countries could be key drivers for long-term growth. However, the pace of adoption and the extent of reimbursement coverage will be critical factors to monitor.